Tracers / [212Pb]Pb-PSC-PEG2-TOC
[212Pb]Pb-PSC-PEG2-TOC
Also written as [212Pb]Pb-PSC-PEG2-TOC; [Pb-212]Pb-PSC-PEG2-TOC
- Radionuclide
- Pb-212 t½ 637.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 6
What it is
- Compound class
- Pb-specific chelator (PSC)-PEG2-conjugated somatostatin analog peptide (TOC/octreotide-based radiopeptide)
- Target / mechanism
- Targets somatostatin receptor subtype 2 (SSTR2) PMID 37955792
- Clinical application
- Targeted alpha-particle radionuclide therapy for SSTR2-positive neuroendocrine tumors PMID 37955792
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Modular-Lab EAZY Eckert & Ziegler | custom manifold | SPE | 94.8 ± 3.0% | 93.8 ± 1.6% | VMT-α-NET (PSC-PEG2-TOC) Perspective Therapeutics Inc. | 39604560 2024 EJNMMI Radiopharm Chem Modular-Lab EAZY module (GTL) — RCYs of 94.8 ± 3.0% |
| Manual synthesis | — | — | — | >95% | PSC-PEG2-TOC | 39884771 2025 J Nucl Med Chelation was performed by incubating 27.5 nmol of peptide per 444 MBq of 212Pb for 10 min at room temperature in 0.4 M ammonium acetate buffer, with a pH of 6.1. |
| Modular-Lab EAZY Eckert & Ziegler | custom manifold | SPE | 94.8 ± 3.0% | 93.8 ± 1.6% | VMT-α-NET (PSC-PEG2-TOC) Perspective Therapeutics Inc. | 39604560 2024 EJNMMI Radiopharm Chem establish the translation of the synthesis to an automated synthesis platform (Modular-Lab EAZY, Eckert&Ziegler) for clinical routine production — the 60-min lasting process stably yielded [212Pb]Pb-VMT-α-NET with RCYs of 94.8 ± 3.0% and RCPs of 93.8 ± 1.6%. |
| — | — | HPLC | >90% | — | PSC-PEG2-TOC | 37955792 2024 Eur J Nucl Med Mol Imaging |
| Manual synthesis | — | HPLC | — | — | PSC-PEG2-TOC | 37955792 2024 Eur J Nucl Med Mol Imaging The radiolabeling and purification process for the preparation of 203Pb/212Pb-labeled peptides followed the methods outlined in a previously published study |
| Manual synthesis | — | — | — | — | PSC-PEG2-TOC | 37955792 2024 Eur J Nucl Med Mol Imaging The radiolabeling and purification process for the preparation of 203Pb/212Pb-labeled peptides followed the methods outlined in a previously published study |
Need this precursor?We can point you to suppliers for [212Pb]Pb-PSC-PEG2-TOC, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); therapeutic radiopharmaceutical -> osmolality (rule); receptor ligand with a saturable target -> molar activity (rule)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [212Pb]Pb-PSC-PEG2-TOC.
Get in touchNotes
Added from reverse module search (stage 6); 2 article(s) with Pb-212. Compound class inferred from precursor name (not stated outright) -- PMID 39884771: 'PSC-PEG2-TOC (PSC-amino-PEG2-acid-d-Phe-cyclo(Cys-Tyr-d-Trp-Lys-Thr-Cys)Thr-OH)'.